SP 1000

Drug Profile

SP 1000

Alternative Names: Cholesterol reducer; SP-1000

Latest Information Update: 19 Jan 2011

Price : $50

At a glance

  • Originator Georgetown University
  • Developer Samaritan Pharmaceuticals
  • Class Antihyperlipidaemics
  • Mechanism of Action Cholesterol inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Hypercholesterolaemia

Most Recent Events

  • 03 Apr 2009 SP 1000 is still in active development
  • 09 May 2007 SP 1000 is still in active development
  • 31 Mar 2006 Preclinical data from a media release have been added to the Hyperlipidaemia pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top